| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T28484 | ||||
| Target Name | Kinesin-like protein KIF11 (KIF11) | ||||
| Type of Target |
Clinical trial |
||||
| Drug Potency against Target | Ispinesib | Drug Info | Ki = 0.6 nM | ||
| Action against Disease Model | Ispinesib | Drug Info | In preclinical studies, ispinesib inhibited growth in a wide range of h uMan and murine cell lines with IC50 values of 1.2-9.5?nM. Treatment of SKOV3 ovarian t uMour cells in vitro with 20?nM of ispinesib, or a Colo 205 colon cancer murine xenograft model with 30?mg?kg?1 of intraperitoneal ispinesib, caused mitotic arrest with cells demonstrating unseparated centrosomes and monopolar mitotic spindles. | [1] | |
| References | |||||
| REF 1 | A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer. 2008 Mar 11;98(5):894-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.